Locus Cell
樂迦再生科技股份有限公司
Locus Cell is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is Elate Ocular (Contract development and manufacturing for international Phase 3 trials, Moderate to severe dry eye; immune-related ocular surface disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| Elate Ocular | — | Contract development and manufacturing for international Phase 3 trials | Moderate to severe dry eye; immune-related ocular surface disease | — | — | Company disclosure |
| Zamto-cel | — | — | — | — | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.